...oral), forodesine) fenretinide (4-hpr) Quisinostat (JNJ-26481585) Suberohydroxamic acid phenyl ester (SHAPE), remetinostat (shp-141, SHAPE) lacutamab (IPH4102) Sofusa anti-PD1 ST-001 nanoFenretinide exoIL-12 TTI-621 (SIRPaFc, SIRPalphaFc) BNZ-1 Cobomarsen...

...data for two compounds, the IgG1 mAb TTI-621...

...data for two compounds, the IgG1 mAb TTI-621...

...million shares at $10.88, which will fund clinical testing of Trillium’s CD47 programs TTI-622 and TTI-621...

...grades of toxicity. Trillium Therapeutics Inc . (TSX:TRIL; NASDAQ:TRIL) data is from IV administration of TTI-621...
...Non-small cell lung cancer (NSCLC) (n=18) 0% 0% 0% 44% Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL) TTI-621...
...CD19 , making CD47 blockade dependent on the presence of CD19. 5) Trillium’s lead compound TTI-621...

...in the dose-expansion portion of the Phase Ia/Ib TTI-621-01 trial showing that IV TTI-621 (SIRPaFc, SIRPalphaFc...
...led to two complete responses and three partial responses, plus six cases of stable disease. TTI-621...
...decoy receptor to block CD47. Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL), Toronto, Ontario Product: TTI-621 (SIRPaFc, SIRPalphaFc...

...mycosis fungoides in the Phase I TTI-621-02 trial showing that intratumoral injection of TTI-621 (SIRPaFc, SIRPalphaFc...
...in 9 patients. In three patients with Sézary syndrome, TTI-621 reduced circulating leukemic Sézary cells. TTI-621...
...decoy receptor to block CD47. Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL), Toronto, Ontario Product: TTI-621 (SIRPaFc, SIRPalphaFc...

...lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL) -33% $7.55 TTI-621...

...testing for acute myelogenous leukemia (AML) and solid tumors. Trillium Therapeutics Inc. has TTI-621 (SIRPaFc; SIRPalphaFc...

...in additional models of NSCLC. Generic chloroquine is marketed for malaria. Trillium Therapeutics Inc. has SIRPaFc...